Biotechnology - UK

Filter

Current filters:

UK

Popular Filters

1 to 25 of 74 results

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

08-10-2014

One of the main messages from the keynote speech at the UK Bioscience Forum by Paul Drayson, chief executive…

BiotechnologyLegalLicensingPatents & Trade marksProductionRegulationResearchSocial IssuesUK

Yale's Stephen Waxman to collaborate with Convergence Pharmaceuticals on chronic pain

Yale's Stephen Waxman to collaborate with Convergence Pharmaceuticals on chronic pain

06-10-2014

Convergence Pharmaceuticals Holdings, focused on developing analgesic medicines, is to collaborate with…

AnalgesiaBiotechnologyConvergence PharmaceuticalsResearchUK

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyItalyMenariniOncologyOxford BioTherapeuticsResearchUK

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

30-09-2014

Avacta Life Sciences, a division of Avacta Group is investing £10 million ($16.2 million) in the launch…

AvactaBiotechnologyResearchUK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

25-09-2014

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCancer Research TechnologyCancer Research UKMedImmuneOncologyResearchUK

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

24-09-2014

The UK’s drug watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgene Corp.OncologyPricingRegulationRevlimidUK

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

17-09-2014

The UK’s Department of Health announced that DCVax-L, the dendritic cell-based vaccine from US company…

BiotechnologyDCVaxNorthwest BiotherapeuticsOncologyRegulationUK

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

15-09-2014

The charity Cancer Research UK and its commercialization arm Cancer Research Technology (CRT), have reached…

Asterias BiotherapeuticsBiotechnologyBioTimeCancer Research TechnologyLicensingOncologyResearchUKVaccines

XenoPort to collaborate with the NIAAA for Horizant trial

XenoPort to collaborate with the NIAAA for Horizant trial

10-09-2014

Neurological biopharma specialist XenoPort is to enter into an agreement with the National Institute…

Alcohol abuseBiotechnologyHorizantNational Institute on Alcohol Abuse and AlcoholismNeurologicalResearchUKXenoPort

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27-08-2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended…

Biogen IdecBiotechnologyCNS DiseasesMultiple sclerosisRegulationTecfideraUK

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Oxford BioMedica appoints former Aeterna Zentaris senior vice president Paul Blake as chief development officer

Oxford BioMedica appoints former Aeterna Zentaris senior vice president Paul Blake as chief development officer

15-08-2014

British gene and cell therapy company Oxford BioMedica has appointed Paul Blake as chief development…

BiotechnologyBoardroomOxford BioMedicaPaul BlakeUK

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

15-08-2014

In further draft guidance published today, UK drugs watchdog the National Institute for Health and Care…

Anti-viralsBiotechnologyGilead SciencesHepatitis CPricingRegulationRibavirinSovaldiUK

UK aims to become world number one in DNA testing with new investment

UK aims to become world number one in DNA testing with new investment

01-08-2014

David Cameron, the UK Prime Minister, has announced a package of investment worth more than £300 million…

BiotechnologyDavid CameronGeneticsIlluminaMedical Research CouncilResearchUK

Life Sciences Hub launched in Wales to support industry

Life Sciences Hub launched in Wales to support industry

17-07-2014

The Welsh Government has today launched the Life Sciences Hub Wales, a national and international focal…

BiotechnologyResearchUKWales

1 to 25 of 74 results

Back to top